[1]
Melo, R.S. and Marques, F.R. 2015. Exclusion payment agreements between reference and generic drug companies: restrictive practices of competition? The Journal of Intellectual Property – Contemporary Law and Constitution. 4, 1 (Feb. 2015), 392–420. DOI:https://doi.org/10.16928/2316-8080.v8n1p.392-420.